Research commonly starts long before a first consultation and can run past a year. The break after a cycle that does not work is part of the journey, not an exit. Attribution windows of 30 or 90 days cannot see any of this, so the channels that actually built the decision get defunded first.
One partner usually researches privately for weeks before the topic is opened jointly. The same page has to work for a solo reader who has told nobody, and later for two people reading it side by side with different questions. Content written for a single decision-maker fails one of those two moments.
Per-cycle price, what the quoted figure includes, what is billed separately, medication spend, storage and annual renewal fees, and what a second cycle costs are the highest-intent questions in the category. Most clinic websites answer none of them, which pushes the entire comparison into a phone call the couple is not ready to make.
Urgency tactics, countdown offers and high-frequency follow-up read as exploitation to people under real distress, and they cost the clinic the referral as well as the case. Restraint is not a softer strategy here. It is the one that gets picked up again 6 months later.
Fertility clinics compete on published success rates that are calculated differently at every clinic and are not comparable across them. We do not build strategy on that ground. We build it on the questions that are genuinely unanswered in the category: what it costs, what happens at each step, and what the clinic does when a cycle does not work.
A published per-cycle price with an itemised line for what is included, what is billed separately, expected medication spend as a range, storage and renewal fees, and financing options. This is the single highest-intent asset in fertility and most clinics do not have one. It also filters enquiries before they reach the counsellor.
Early-stage material written for one person reading privately, with no assumption the partner knows yet, and comparison material built to be opened on a laptop by 2 people. Different formats, different tone, same factual base.
What a review consultation covers, what changes between cycle 1 and cycle 2, how pricing works on a repeat cycle, and how long a couple can take before deciding. This is the moment competitors are silent, and silence is why patients switch clinics rather than continue.
Named clinicians, laboratory and embryology practice described in plain terms, consultation structure, waiting times, and what the couple physically does each week. Process detail is verifiable, publishable and defensible. A success-rate claim is none of those things.
Cost, process and what-happens-next questions are exactly the queries people now put to AI assistants, precisely because they are too private to ask a person. Health answers use the strictest source selection of any category, so the sourcing, attribution and entity work has to be done properly to be quoted at all.
A contact programme measured in months, designed to survive a deliberate pause, with clear opt-down rather than opt-out, and a hard stop on follow-up frequency. Built to be re-opened by the couple, not chased by the clinic.
Almost every healthcare funnel assumes forward motion. Fertility does not move forward continuously. It runs for months, stalls while a couple saves or decides, frequently stops after a cycle that does not work, and restarts weeks or months later with a different set of questions and often a different clinic on the shortlist. A campaign that treats the gap as a lost lead spends its budget re-acquiring people it already had. We plan fertility acquisition as one long cohort with a deliberate quiet period in the middle, and we measure it that way.
Cost, process and after-a-cycle content built for a decision researched over months, first alone and then jointly.
Presence in AI-generated answers, where private questions about cost and process are increasingly asked instead of being typed into a search box.
Published per-cycle pricing, inclusions and exclusions, medication ranges, storage and renewal fees, and financing pathways.
Contact programmes measured in months, built to survive a pause and to be restarted by the patient with capped follow-up frequency.
Campaign structures that work inside fertility targeting restrictions, with device-sharing suppression rules and creative reviewed for privacy exposure.
Cohort measurement from first touch to consultation to cycle started, with repeat cycles and patient referrals attributed back to source.
Published rates are not standardised, use different denominators, and depend heavily on which patients a clinic takes on, so they are not comparable between clinics. upGrowth does not make or amplify outcome claims. Beyond the compliance exposure, a position built on being the higher number is commercially fragile: it collapses the moment a competitor publishes a bigger one, and it invites the regulatory attention nobody in this category wants.
Section 22 of the PCPNDT Act, 1994 prohibits advertising relating to pre-natal sex determination in any form including the internet, and Section 32 of the ART (Regulation) Act, 2021 does the same for sex-selective treatment. The rule that shapes everyday copy, though, is the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954: item 48 on its Schedule is sterility in women, so copy cannot suggest a product diagnoses, cures, mitigates, treats or prevents it. Ad copy, landing pages, agency-written blog content and social posts all sit inside that perimeter, and under Sections 2(d) and 9 the agency that writes and places the ad carries liability alongside the clinic. Legal review before publication is not a formality here.
Major platforms limit fertility-related audience targeting and personalised remarketing, so policy has to be checked directly before any campaign and channel concentration is a business risk. There is a second problem platforms do not solve: a remarketing creative served on a shared household device or a shared browser can disclose to a family member that someone is researching treatment. Suppression rules and creative restraint here are a privacy obligation, not a preference.
Enquiry volume is dominated by people who are years away from treatment or who will not proceed for reasons only the clinic can assess. Broadening traffic will improve cost per lead and change nothing downstream. The number that governs the business is cost per cycle started, or cost per consultation that converts to a cycle.
We work across regulated healthcare, where claims are restricted and every published line has to be defensible. Fertility is a category built on numbers nobody can verify, so what we bring is the opposite: published cost, published process, and measurement that reaches all the way to a cycle started.
Most of our healthcare work sits in specialties where results cannot be advertised at all, so building demand from process detail, cost clarity and named clinical authority is our normal mode rather than a fallback. Fertility runs under the same constraint.
Cohort measurement from first touch through consultation to cycle started, with repeat cycles and patient referrals attributed back to source. A funnel that runs for months cannot be read on a monthly report, and this is the single change that most often reverses a fertility budget decision.
A documented cap on follow-up frequency, opt-down rather than opt-out, and a written position that we will not build conversion pressure aimed at people under real distress. If that costs short-term enquiry volume, we say so at the proposal stage rather than after.
Cost and process questions in fertility are precisely the ones people now put to an AI assistant rather than to a person. Generative engine optimisation runs here as a named service, and health carries the strictest source selection of any category, so the sourcing and attribution work has to be deliberate.
Cost per lead does not just understate performance here. It inverts it. Take an illustrative month: 200 enquiries, 40 consultations, 10 cycles started. Buy broader traffic and enquiries go to 400 while consultations stay at 40, because the added volume is people who are years away from treatment. Cost per lead halves, the dashboard turns green, and the clinic funds more of the thing that produced no cycles. The counsellor team meanwhile absorbs double the call load for the same 10 cycles.
The number that governs the business is cost per cycle started, reported by cohort rather than by month, because the couple who enquired in March may start in November and the cycle does not belong to November’s spend. Two more lines belong on the same report: repeat cycles, and cycles traceable to a patient referral. Fertility is a private topic, which makes the person who has been through it an unusually strong referral source, successful cycle or not, and that referral is almost never attributed to the campaign that acquired them. A clinic optimising to cost per lead is systematically defunding the thing that produces its best cases.
The underlying problem is one we have written about across healthcare: when price is opaque, the entire comparison moves into a phone call, and the clinic that publishes first stops competing on who chases hardest. We cover that mechanism in Pain in the Wallet, our field note on what cost opacity does to a healthcare funnel.
The operating detail sits in the healthcare content compliance playbook, a free PDF from our healthcare programme.